The relationship of urocortin-2 with insulin resistance patients having PCOS

Abstract

In this study, we aimed to compare the serum urocortin-2 (UCN2) levels in women with polycystic ovary syndrome (PCOS) and healthy women. Thirty-eight patients with PCOS and 41 healthy women were included in the study whose age and BMI matched. The fasting serum glucose, insulin, free testosterone, hs-CRP and UCN2 levels of the all participants were examined. HOMA-IR formula was used in order to calculate the insulin resistance. Circulating UCN2 levels were significantly elevated in women with PCOS compared with controls (142.93 ± 59.48 versus 98.56 ± 65.01 pg/ml, p = 0.002). FBG, serum insulin, hs-CRP and HOMA-IR levels were found to be increased in women with PCOS. There was a positive correlation between UCN2 and free-testosterone in only PCOS group (r = 0.235, p = 0.027). Multivariate logistic regression analyses revealed that the odds ratio for PCOS was 2.31 for patients in the highest quartile of UCN2 compared with those in the lowest quartile (OR = 2.31, 95% CI = 1.88-2.83, p=0.021). Multiple linear regression analysis revealed that HOMA-IR, hs-CRP and free-testosterone independently predicted UCN2 levels (p < 0.05). UCN2 levels were significantly higher in PCOS cases when compared to control group. UCN2 is thought to be effective on pathophysiology of PCOS by paracrine and autocrine pathways.

Assessment of clinical data on urocortins and their therapeutic potential in cardiovascular diseases: A systematic review and meta‐analysis

“…21,39,42,43 Interestingly, we did not find remarkable differences among Ucn types and in their association with specific cardiovascular diseases. Moreover, blood Ucn levels appear to increase in a number of other general systemic challenges, including metabolic syndrome, 49 PCOS, 53,54 or type 2 diabetes mellitus. 48,49 Thus, increases in Ucn levels may not even be specific for cardiovascular disorders or HF.…”

“…In case of Ucn3, higher hormone levels were demonstrated for a number of pathological conditions, such as metabolic syndrome, diabetes mellitus type 2, polycystic ovary syndrome (PCOS), or obesity, but not for HF or for other cardiovascular diseases. 48,49,53 Because all Ucn levels were determined by ELISA techniques, gross differences in measurement could not contribute to the substantial heterogeneity of our results. Other factors, such as BMI, age, and sex, may have contributed to the heterogeneity of these findings.…”

“…In case of Ucn3, higher hormone levels were demonstrated for a number of pathological conditions, such as metabolic syndrome, diabetes mellitus type 2, polycystic ovary syndrome (PCOS), or obesity, but not for HF or for other cardiovascular diseases. 48 , 49 , 53 …”

MicroRNA-33b-5p is overexpressed and inhibits GLUT4 by targeting HMGA2 in polycystic ovarian syndrome: An in vivo and in vitro study

“…Both excess extracellular glucose and insulin suppressed the levels of GLUT4, SREBF1 and HMGA2 by upregulating miR-33b-5p, whereas GLUT4, SREBF1 and HMGA2 levels became elevated when miR-33b-5p was inhibited, indicating the powerful effects that glucose and insulin exert in the regulation of GLUT4, SREBF1 and HMGA2 by miR-33b-5p. Insulin resistance is a main feature of PCOS, and can adversely affect a woman's health (8,44,45). GLUT4 is strongly linked to the development of insulin resistance in type 2 diabetes or PCOS (46,47).…”

Chronic UCN2 Treatment Desensitizes CRHR2 and Improves Insulin Sensitivity

“…Germline UCN2 KO animals have improved glucose tolerance that is worsened following UCN2 re-administration (Chen et al, 2006). Treatment of animals with CRHR2 antagonists improves glucose tolerance (Chen et al, 2006) and humans in the upper quartile range of circulating UCN2 have increased insulin resistance risk (Temur et al, 2017). These ndings indicate a role for UCN2 as an insulin desensitizer.…”